90/015,171GENETICALLY MODIFIED RAT MODELS FOR SEVERE COMBINED IMMUNODEFICIENCY (SCID)11,089,765Closed
Status
Reexamination Certificate Issued
Requester
Unknown
Requester Law Firm
Requested By
Third Party
Patent Owner
P.O. Law Firm
Reexam History (34 events)
Dec 2, 2023CCRDYApplication ready for PDX access by participating foreign offices
Dec 1, 2023REEXInput Issue Number and Issue Date for Reexamination
Oct 9, 2023RXPUBSReexam Forwarded to Office of Publications
Sep 26, 2023MRNRCRX - Mail Notice of Intent to Issue a Reexam Certificate
Sep 14, 2023IDSCInformation Disclosure Statement considered
Jul 26, 2023WIDSInformation Disclosure Statement (IDS) Filed
Jul 26, 2023RXAF/DAffidavit(s), Declaration(s) and/or Exhibit(s) Filed
Jul 26, 2023RXA...Response after Non-Final Action
May 26, 2023MR.NFRX - Mail Reexam Non-Final Action
Apr 18, 2023RXFWDXDate Forwarded to Examiner
Feb 16, 2023MREXORX - Mail Ex Parte Request for Reexamination Granted
Jan 31, 2023NRX.Notice of Reexam Published in Official Gazette
Dec 28, 2022IDSCInformation Disclosure Statement considered
Dec 12, 2022MRPWPRX - Mail Pilot Waiver Program - Ex Parte Interview Summary
Dec 12, 2022DOCKCase Docketed to Examiner in GAU
Dec 7, 2022CRFECRF Is Good Technically / Entered into Database
Dec 6, 2022RXTTLRPTTitle Report
Dec 6, 2022MRXNReexamination Formalities Notice Mailed
Dec 6, 2022MRXNReexamination Formalities Notice Mailed
Dec 5, 2022SMALApplicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27
Dec 5, 2022RXPCOMCompletion of Preprocessing - Released to Assigned GAU
Dec 5, 2022RXNREQFDNotice of reexamination request filing date
Dec 5, 2022RXNREQAUNotice of assignment of reexamination request
Dec 5, 2022BIG.Entity Status Set To Undiscounted (Initial Default Setting or Status Change)
Dec 1, 2022RXLITSRReexam Litigation Search Conducted
Dec 1, 2022PRXRParalegal Reexam Review Complete
Dec 1, 2022FTFIFITF set to NO - revise initial setting
Nov 30, 2022WIDSInformation Disclosure Statement (IDS) Filed
Nov 30, 2022RXOSUB.RReexamination requested by third party requester
Nov 30, 2022RXOSUBReceipt of Original Ex Parte Reexam Request
Nov 30, 2022RXO_40.RReceipt of Orig. Ex Parte Request by Third Party Less Than 40 Pages - Rule 1.20(c )(1)
Nov 30, 2022RXIDS.RReexam - Information Disclosure Statement Filed by Third Party Requester
Nov 30, 2022RXC/SRCertificate of Service
Nov 30, 2022BIG.Entity Status Set To Undiscounted (Initial Default Setting or Status Change)
Prosecution, PTAB & CAFC
PTAB Proceedings (IPR, PGR, CBM, DER)
None found
Federal Circuit (CAFC)
None found
Terminal Disclaimer
Filed — ApprovedFeb 12, 2021
Prosecution History
| Date | Code | Description |
|---|---|---|
| Feb 13, 2021 | P574 | PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED |
| Feb 12, 2021 | DIST | Terminal Disclaimer Filed |
Maintenance Fees
Grant
Aug 17, 2021
3.5-yr
Feb 17, 2025
Paid Jan 9, 2025
7.5-yr
Feb 17, 2029
11.5-yr
Feb 17, 2033
Expiry
Feb 13, 2039
Entity Status
Small Entity
Expires
Feb 13, 2039 (12.9 yr remaining)
Term Adjustment
+457 days (~1.3 yr)
Assignments
AssignmentReel/Frame: 053073/0069Recorded: Jun 29, 2020
From
JOHN STUART CRAWFORDInventor
May 31, 2013
ERIC M. OSTERTAGInventor
May 30, 2013
JOSEPH RUIZInventor
May 31, 2013
→
To
TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
OtherReel/Frame: 055104/0239Recorded: Jan 25, 2021
From
TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
Nov 27, 2018
→
To
HERA TESTING LABORATORIES, INC.